Page last updated: 2024-11-06

ecabapide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID65885
CHEMBL ID2104348
SCHEMBL ID637042
MeSH IDM0162665

Synonyms (30)

Synonym
ecabamide
muralis
ecabapide
dq-2511
m-((((3,4-dimethoxyphenethyl)carbamoyl)methyl)amino)-n-methylbenzamide
benzamide, 3-((2-((2-(3,4-dimethoxyphenyl)ethyl)amino)-2-oxoethyl)amino)-n-methyl-
ccris 7698
ecabapide [inn]
dq2511
dq 2511
3-((2-((2-(3,4-dimethoxyphenyl)ethyl)amino)-2-oxoethyl)amino)-n-methylbenzamide
AKOS000279039
3-[[2-[2-(3,4-dimethoxyphenyl)ethylamino]-2-oxoethyl]amino]-n-methylbenzamide
104775-36-2
unii-4ka5whl8t2
4ka5whl8t2 ,
CHEMBL2104348
ecabapide [mi]
ecabapide [jan]
SCHEMBL637042
Z52799962
MLS006011526
smr004703298
DTXSID80146718
SR-01000945217-1
sr-01000945217
FT-0720607
Q27259863
EN300-1700036
3-[({[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}methyl)amino]-n-methylbenzamide

Research Excerpts

Effects

ExcerptReferenceRelevance
"Ecabapide (DQ-2511) has been demonstrated to be effective in preventing water-immersion restraint stress ulceration of rats. "( [Effects of 2-(3,4-dimethoxyphenyl)ethylamine derivative (ecabapide, DQ-2511) and its metabolites on water-immersion restraint stress-induced gastric ulcers in rats].
Furuhama, K; Hosokami, T; Tabuchi, Y, 1995
)
1.98

Dosage Studied

14C-Ecabapide, 3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl]methyl]amino-N- methyl[14C]benzamide was dosed orally to rat (100 mg/kg)

ExcerptRelevanceReference
" 14C-Ecabapide, 3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl]methyl]amino-N- methyl[14C]benzamide, was dosed orally to rat (100 mg/kg)."( Identification of urinary metabolites of ecabapide in rat.
Fujimaki, Y; Hosokami, T; Ono, K, 1995
)
1.07
" In addition to this effect, it produced an increase in respiratory rate, a decrease in blood pressure and a slight increase in heart rate after dosing at 50 mg/kg."( Cardiovascular properties of the new anti-ulcer drug 3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl]methyl]-amino-N- methylbenzamide.
Asano, M; Hirohashi, M; Ryokawa, Y; Takasuna, K; Tamura, K, 1993
)
0.29
"A previous study revealed that DQ-2511, a new gastroprokinetic drug, induced hemolytic anemia together with increased Heinz body formation, preceded by a marked decrease in erythrocyte reduced glutathione (GSH) content, after 2 weeks of dosing onward in dogs."( A possible mechanism of heinz body hemolytic anemia induced by DQ-2511, a new gastroprokinetic drug, in dogs.
Nomura, M; Ohno, H; Watanabe, K, 1996
)
0.29
"Thirteen-week oral repeated dose toxicity of ecabapide, a gastroprokinetic drug, was investigated in dogs at dosage levels of 50, 175 or 600 mg/kg, and in rats at dosage levels of 25, 100, 400 or 1600 mg/kg."( Thirteen-week repeated oral dose toxicity study of ecabapide, a gastroprokinetic drug, in dogs and rats.
Akiyama, Y; Genda, Y; Jindo, T; Kakihata, K; Ohno, H, 1998
)
0.81
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (8.00)18.7374
1990's22 (88.00)18.2507
2000's1 (4.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]